APRE

Company Overview — What Does Aprea Therapeutics, Inc. Do?

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246, a small molecule p53 reactivator, which is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML); Phase I clinical trials for the treatment of relapsed/refractory TP53 mutant chronic lymphoid leukemia; and Phase I/II clinical trials in relapsed/refractory gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator, which is in Phase I clinical trials for the treatment of MDS and AML. The company was founded in 2006 and is headquartered in Boston, Massachusetts. Aprea Therapeutics, Inc. (APRE) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Oren Gilad. With a market capitalization of $8M, APRE is one of the notable companies in the Healthcare sector.

Aprea Therapeutics, Inc. (APRE) Stock Rating — Avoid (April 2026)

As of April 2026, Aprea Therapeutics, Inc. receives a Avoid rating with a composite score of 25.3/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.APRE ranks #4,301 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Aprea Therapeutics, Inc. ranks #785 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

APRE Stock Price and 52-Week Range

Aprea Therapeutics, Inc. (APRE) currently trades at $0.90. The stock gained $0.17 (22.6%) in the most recent trading session. The 52-week high for APRE is $2.65, which means the stock is currently trading -66.0% from its annual peak. The 52-week low is $0.55, putting the stock 64.2% above its annual trough. Recent trading volume was 1.5M shares, reflecting moderate market activity.

Is APRE Overvalued or Undervalued? — Valuation Analysis

Aprea Therapeutics, Inc. (APRE) carries a value factor score of 9/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.65x, versus the sector average of 2.75x. The price-to-sales ratio is 12.78x, compared to 1.66x for the average Healthcare stock.

At current multiples, Aprea Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Aprea Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Aprea Therapeutics, Inc. (APRE) earns a quality factor score of 20/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -111.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -87.4% versus the sector average of -33.1%.

On a margin basis, Aprea Therapeutics, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -43807.1% (sector: -66.1%). Net profit margin stands at -41768.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -99.7% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

APRE Debt, Balance Sheet, and Financial Health

Aprea Therapeutics, Inc. has a debt-to-equity ratio of 28.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.63x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $14M.

APRE has a beta of 0.61, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Aprea Therapeutics, Inc. is 38/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Aprea Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Aprea Therapeutics, Inc. reported revenue of $637,043 and earnings per share (EPS) of $-1.93. Net income for the quarter was $-14M. Gross margin was 100.0%. Operating income came in at $-15M.

In FY 2025, Aprea Therapeutics, Inc. reported revenue of $285,759 and earnings per share (EPS) of $-1.93. Net income for the quarter was $-13M. Revenue grew -81.0% year-over-year compared to FY 2024. Operating income came in at $-13M.

In Q3 2025, Aprea Therapeutics, Inc. reported revenue of $1,848 and earnings per share (EPS) of $-0.47. Net income for the quarter was $-3M. Revenue grew -99.5% year-over-year compared to Q3 2024. Operating income came in at $-3M.

In Q2 2025, Aprea Therapeutics, Inc. reported revenue of $118,111 and earnings per share (EPS) of $-0.53. Net income for the quarter was $-3M. Revenue grew -79.0% year-over-year compared to Q2 2024. Operating income came in at $-3M.

Over the past 8 quarters, Aprea Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $561,574 to $637,043. Investors analyzing APRE stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

APRE Dividend Yield and Income Analysis

Aprea Therapeutics, Inc. (APRE) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

APRE Momentum and Technical Analysis Profile

Aprea Therapeutics, Inc. (APRE) has a momentum factor score of 14/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 66/100 reflects moderate short selling activity.

APRE vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Aprea Therapeutics, Inc. (APRE) ranks #785 out of 838 stocks based on the Blank Capital composite score. This places APRE in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing APRE against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full APRE vs S&P 500 (SPY) comparison to assess how Aprea Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

APRE Next Earnings Date

No upcoming earnings date has been announced for Aprea Therapeutics, Inc. (APRE) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy APRE? — Investment Thesis Summary

The quantitative profile for Aprea Therapeutics, Inc. suggests caution. The quality score of 20/100 flags below-average profitability. The value score of 9/100 indicates premium valuation. Momentum is weak at 14/100, a headwind for near-term performance. High volatility (stability score 38/100) increases portfolio risk.

In summary, Aprea Therapeutics, Inc. (APRE) earns a Avoid rating with a composite score of 25.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on APRE stock.

Related Resources for APRE Investors

Explore more research and tools: APRE vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare APRE head-to-head with peers: APRE vs AZN, APRE vs SLGL, APRE vs VMD.